PE20190970A1 - Anticuerpos anti-cd40 y sus usos - Google Patents

Anticuerpos anti-cd40 y sus usos

Info

Publication number
PE20190970A1
PE20190970A1 PE2018003115A PE2018003115A PE20190970A1 PE 20190970 A1 PE20190970 A1 PE 20190970A1 PE 2018003115 A PE2018003115 A PE 2018003115A PE 2018003115 A PE2018003115 A PE 2018003115A PE 20190970 A1 PE20190970 A1 PE 20190970A1
Authority
PE
Peru
Prior art keywords
seq
chain
cdr1
cdr2
cdr3
Prior art date
Application number
PE2018003115A
Other languages
English (en)
Inventor
Diane Hollenbaugh
Shiming Ye
Diane Sau Mun COHEN
Original Assignee
Abbvie Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Biotherapeutics Inc filed Critical Abbvie Biotherapeutics Inc
Publication of PE20190970A1 publication Critical patent/PE20190970A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

SE REFIERE A UN ANTICUERPO O FRAGMENTO DE UNION ANTI-CD40 QUE COMPRENDE I) UNA CADENA VH QUE COMPRENDE TRES CDR, DONDE LA CDR1 ES DE SEC ID NO: 8, LA CDR2 ES DE SEC ID NO: 18 Y LA CDR3 ES DE SEC ID NO: 35; Y II) UNA CADENA VL QUE COMPRENDE TRES CDR, DONDE LA CDR1 ES DE SEC ID NO: 56, LA CDR2 ES DE SEC ID NO: 68 Y LA CDR3 ES DE SEC ID NO: 88; EN DONDE LA CADENA VH ES DE SEC ID NO: 117 Y LA CADENA VL ES DE SEC ID NO: 170. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE DICHO ANTICUERPO QUE ES UTIL EN EL TRATAMIENTO DE CANCER
PE2018003115A 2016-05-27 2017-05-26 Anticuerpos anti-cd40 y sus usos PE20190970A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662342417P 2016-05-27 2016-05-27

Publications (1)

Publication Number Publication Date
PE20190970A1 true PE20190970A1 (es) 2019-07-09

Family

ID=59014833

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018003115A PE20190970A1 (es) 2016-05-27 2017-05-26 Anticuerpos anti-cd40 y sus usos

Country Status (34)

Country Link
US (8) US10519243B2 (es)
EP (2) EP3464361B1 (es)
JP (2) JP2019523221A (es)
KR (2) KR20220028143A (es)
CN (1) CN109476750B (es)
AR (2) AR108611A1 (es)
AU (1) AU2017271602A1 (es)
BR (1) BR112018074468A2 (es)
CA (1) CA3025347A1 (es)
CL (1) CL2018003366A1 (es)
CO (1) CO2018012699A2 (es)
CR (1) CR20180605A (es)
CY (1) CY1124806T1 (es)
DO (1) DOP2018000258A (es)
EC (1) ECSP18094829A (es)
ES (1) ES2901722T3 (es)
HR (1) HRP20211882T1 (es)
HU (1) HUE056670T2 (es)
IL (1) IL263223B2 (es)
LT (1) LT3464361T (es)
MX (1) MX2018014630A (es)
MY (1) MY195442A (es)
NZ (1) NZ748644A (es)
PE (1) PE20190970A1 (es)
PH (1) PH12018502456A1 (es)
PL (1) PL3464361T3 (es)
PT (1) PT3464361T (es)
RS (1) RS62726B1 (es)
RU (1) RU2752049C2 (es)
SG (2) SG11201810522UA (es)
SI (1) SI3464361T1 (es)
TW (2) TWI761348B (es)
UA (1) UA123111C2 (es)
WO (1) WO2017205742A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008318357B2 (en) * 2007-11-01 2015-01-22 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to eimeria
US10519243B2 (en) * 2016-05-27 2019-12-31 Abbvie Biotherapeutics Inc. Anti-CD40 antibodies
US11976123B2 (en) 2018-04-20 2024-05-07 Lyvgen Biopharma Holdings Limited Anti-CD40 antibodies and uses thereof
AU2019383548A1 (en) 2018-11-23 2021-06-24 Strike Pharma Ab Bi-specific conjugates
AU2019389354A1 (en) * 2018-11-30 2021-07-15 Jiangsu Hengrui Medicine Co., Ltd. Anti-CD40 antibody, antigen binding fragment and pharmaceutical use thereof
CN111548415B (zh) * 2019-03-04 2021-04-20 北京天广实生物技术股份有限公司 与cd40特异结合的抗体及其用途
KR20220004985A (ko) 2019-03-27 2022-01-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) Cd40 활성화 특성을 가진 재조합 단백질
WO2020207470A1 (zh) * 2019-04-10 2020-10-15 南开大学 抗cd40抗体及其用途
EP4027998A1 (en) 2019-09-09 2022-07-20 Basilea Pharmaceutica International AG Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases
AU2019465294A1 (en) * 2019-09-11 2022-03-24 Novartis Ag A method for preventing human virus associated disorders in patients
CN115038718A (zh) * 2019-11-08 2022-09-09 先声（上海）医药有限公司 抗人程序性死亡配体-1（pd-l1）的抗体及其用途
IL293450A (en) * 2019-12-03 2022-07-01 Evotec Int Gmbh Interferon-related antigen-binding proteins and uses thereof
GB202008003D0 (en) 2020-05-28 2020-07-15 Quine Medical Ab Anti-CD40 antibody
EP4185320A1 (en) * 2020-07-23 2023-05-31 Dyne Therapeutics, Inc. Muscle-targeting complexes and uses thereof in treating muscle atrophy
CN115403670A (zh) * 2021-05-26 2022-11-29 安徽瀚海博兴生物技术有限公司 抗cd40抗体及其用途
WO2024059899A1 (en) * 2022-09-20 2024-03-28 Currus Biologics Pty Ltd Bispecific polypeptides and uses thereof

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
AU5632296A (en) 1995-04-27 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
WO1998024893A2 (en) 1996-12-03 1998-06-11 Abgenix, Inc. TRANSGENIC MAMMALS HAVING HUMAN IG LOCI INCLUDING PLURAL VH AND Vλ REGIONS AND ANTIBODIES PRODUCED THEREFROM
JP3876002B2 (ja) 1997-04-14 2007-01-31 ミクロメート・アクチエンゲゼルシャフト 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
ATE384792T1 (de) 1998-11-18 2008-02-15 Genentech Inc Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern
US6946129B1 (en) * 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
EP1253942A4 (en) 2000-02-01 2004-06-16 Tanox Inc CD40-BINDING AND APC-ACTIVATING MOLECULES
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
CA2551008C (en) * 2003-12-25 2013-10-01 Kirin Beer Kabushiki Kaisha Anti-cd40 antibody mutants
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
WO2006017173A1 (en) * 2004-07-10 2006-02-16 Alexion Pharmaceuticals, Inc. Methods for discovering antibodies specific to cancer cells and antibodies discovered thereby
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
PL2066349T3 (pl) * 2006-09-08 2012-09-28 Medimmune Llc Humanizowane przeciwciała anty-CD19 i ich zastosowanie w leczeniu nowotworów, transplantacjach i leczeniu chorób autoimmunologicznych
RU2538709C2 (ru) * 2007-10-05 2015-01-10 Дженентек, Инк. Гуманизированное антитело
RS60612B1 (sr) * 2010-03-31 2020-08-31 Boehringer Ingelheim Int Anti-cd40 antitela
SG194701A1 (en) 2011-04-29 2013-12-30 Apexigen Inc Anti-cd40 antibodies and methods of use
GB201115280D0 (en) * 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
DK2889377T3 (da) * 2012-08-24 2020-03-30 Chugai Pharmaceutical Co Ltd Fc?RIIb-Specifik Fc-regionsvariant
JP6693745B2 (ja) * 2012-10-30 2020-05-13 アペクシジェン， インコーポレイテッド 抗ｃｄ４０抗体および使用方法
EP2970436B1 (en) 2013-03-15 2018-09-05 AbbVie Biotherapeutics Inc. Fc variants
GB201322583D0 (en) * 2013-12-19 2014-02-05 Alligator Bioscience Ab Antibodies
SG10201913099YA (en) 2014-10-29 2020-02-27 Seattle Genetics Inc Dosage and administration of non-fucosylated anti-cd40 antibodies
AR104809A1 (es) * 2015-05-29 2017-08-16 Abbvie Inc Anticuerpos anti-cd40 y usos de los mismos
US10519243B2 (en) * 2016-05-27 2019-12-31 Abbvie Biotherapeutics Inc. Anti-CD40 antibodies
TW201806972A (zh) * 2016-05-27 2018-03-01 美商艾伯維生物醫療股份有限公司 雙特異性結合蛋白

Also Published As

Publication number Publication date
EP3995511A1 (en) 2022-05-11
SG11201810522UA (en) 2018-12-28
AR124692A2 (es) 2023-04-26
PL3464361T3 (pl) 2022-01-31
RU2018146533A3 (es) 2020-06-29
US10597460B2 (en) 2020-03-24
MX2018014630A (es) 2019-06-10
EP3464361A1 (en) 2019-04-10
UA123111C2 (uk) 2021-02-17
TW202229356A (zh) 2022-08-01
EP3464361B1 (en) 2021-11-10
US20180186889A1 (en) 2018-07-05
TWI761348B (zh) 2022-04-21
US20170342159A1 (en) 2017-11-30
TWI814279B (zh) 2023-09-01
TW201806971A (zh) 2018-03-01
CY1124806T1 (el) 2022-11-25
US20220119542A1 (en) 2022-04-21
MY195442A (en) 2023-01-21
IL263223A (en) 2018-12-31
BR112018074468A2 (pt) 2019-03-06
ECSP18094829A (es) 2019-03-29
KR20220028143A (ko) 2022-03-08
US10023645B1 (en) 2018-07-17
US10519243B2 (en) 2019-12-31
AR108611A1 (es) 2018-09-05
WO2017205742A1 (en) 2017-11-30
US20200010558A1 (en) 2020-01-09
PT3464361T (pt) 2021-12-27
HRP20211882T1 (hr) 2022-03-04
RU2752049C2 (ru) 2021-07-22
HUE056670T2 (hu) 2022-02-28
JP2022068294A (ja) 2022-05-09
RU2018146533A (ru) 2020-06-29
AU2017271602A1 (en) 2018-12-13
CN109476750B (zh) 2022-02-01
NZ748644A (en) 2023-05-26
KR20190014524A (ko) 2019-02-12
CN109476750A (zh) 2019-03-15
US20210277137A1 (en) 2021-09-09
IL263223B2 (en) 2023-03-01
RS62726B1 (sr) 2022-01-31
SG10201914132RA (en) 2020-03-30
LT3464361T (lt) 2022-01-10
JP7331179B2 (ja) 2023-08-22
IL263223B (en) 2022-11-01
US20190071509A1 (en) 2019-03-07
KR102366355B1 (ko) 2022-02-24
US10400041B2 (en) 2019-09-03
CL2018003366A1 (es) 2019-03-15
ES2901722T3 (es) 2022-03-23
CO2018012699A2 (es) 2019-08-20
US20210024642A1 (en) 2021-01-28
CR20180605A (es) 2020-01-13
CA3025347A1 (en) 2017-11-30
DOP2018000258A (es) 2019-02-15
SI3464361T1 (sl) 2022-01-31
JP2019523221A (ja) 2019-08-22
PH12018502456A1 (en) 2019-10-21
US20200040090A1 (en) 2020-02-06
US10844131B2 (en) 2020-11-24

Similar Documents

Publication Publication Date Title
PE20190970A1 (es) Anticuerpos anti-cd40 y sus usos
PE20191208A1 (es) Anticuerpos anti-cd73 y usos de los mismos
PH12018501554A1 (en) Ror1 antibody compositions and related methods
CL2019001926A1 (es) Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017).
PE20171180A1 (es) Anticuerpos anti-pd-1 y sus metodos de uso
PE20180499A1 (es) Anticuerpos de union a tau
PE20191102A1 (es) Anticuerpos anti-pd-1 y sus usos
EA201991577A1 (ru) Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер
PE20191131A1 (es) Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) activables y sus usos
CL2018003583A1 (es) Anticuerpos anti-pd-l1 y usos de los mismos.
PE20170912A1 (es) Conjugados de anticuerpo-farmaco
PE20171654A1 (es) Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
PE20181805A1 (es) Composiciones y anticuerpos anti-tim-3
PE20170125A1 (es) Receptor antigenico quimerico (car) que comprende un dominio de union de antigenos, el cual se une selectivamente a la region constante del tcr beta 1 (trbc1) o trbc2 de celulas t
PE20142243A1 (es) Anticuerpos que se unen a ox40 y sus usos
PE20180927A1 (es) Moleculas de union a lag-3 y metodos de uso de las mismas
PE20221580A1 (es) Anticuerpos terapeuticos y sus usos
PE20180926A1 (es) Anticuerpos contra el miembro 4 de la superfamilia del receptor del factor de necrosis tumoral (ox40) y sus usos
PE20161571A1 (es) Anticuerpos anti-ox40 y metodos de uso
PE20130159A1 (es) Anticuerpos anti-cd40
AR096617A1 (es) Anticuerpos anti-tweakr y sus usos
PE20131403A1 (es) Anticuerpos anti-ox40 y metodos de uso de los mismos
PE20131209A1 (es) Anticuerpos anti-fap
PE20190737A1 (es) Anticuerpos anti-cd27